In its phase 1 trial, NBTXR3 showed promise:
http://meetinglibrary.asco.org/content/127447-144
The phase 2/3 trial is still going on in Europe:
https://clinicaltrials.gov/ct2/show/NCT02379845
Anybody on the trial?
Results of phase 1 trial for NBTXR3 were just published:
http://clincancerres.aacrjournals.org/content/early/2016/10/06/1078-0432.CCR-16-1297
The phase II/III trial of NBTXR3 got the approval from the Independent Data Monitoring Committee to continue. It is still recruiting and results should be available at the end of the year: